Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
709 Leser
Artikel bewerten:
(2)

Hokkori USA: REMORY, a Supplement Currently Receiving Widespread Attention, Announces Packaging Redesign for the U.S. Market

REMORY: Elevate Cognitive Health with Unique Sea Squirt-Derived Plasmalogens. Now in the U.S., this Japanese-Innovated Supplement Combines EPA, DHA, and Omega-3s for Enhanced Memory and Brain Function in Aging Adults. Recognized by Japan as a 'Food with Functional Claims,' REMORY is FDA-Notified, Setting a New Standard in Natural Cognitive Support.

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / Since its launch in the United States, the supplement REMORY®, which contains plasmalogen believed to be effective in preventing cognitive decline, has experienced a 20% monthly increase in sales, with over 90% of customers being repeat buyers and more than half being regular subscribers, leading to significant attention. To have even more people enjoy our product, we have redesigned the packaging for the U.S. market in line with our increased production.

REMORY
REMORY: Elevate Cognitive Health with Unique Sea Squirt-Derived Plasmalogens. Now in the U.S., this Japanese-Innovated Supplement Combines EPA, DHA, and Omega-3s for Enhanced Memory and Brain Function in Aging Adults.

Since its launch, Hokkori USA, an authorized distributor known for its commitment to quality and customer satisfaction, has received various comments from middle-aged and older adults in the U.S. who have experienced the product's benefits, and inquiries from many retailers have been pouring in. Additionally, we plan to launch media advertisements to reach an even wider audience.

REMORY® contains plasmalogens, which play an important role in maintaining cognitive function in the human brain. This supplement is especially suitable for middle-aged and older adults concerned about memory decline. Unlike other plasmalogens, REMORY® uses plasmalogens derived from sea squirts (ascidians), a source known for its rich content of not only plasmalogens but also EPA, DHA, and Omega-3 fatty acids. The primary ingredient in REMORY® is high-quality sea squirts sourced from Hokkaido, Japan.

REMORY® is known as the only sea squirt-derived plasmalogen supplement in the U.S. market that has been approved by the Japanese Government to be labeled as a "Food with Functional Claims" and is expected to enhance memory and brain function in the elderly, setting a new standard for natural cognitive support.

In Japan, where aging is rapidly advancing globally, there is a high demand for products that help maintain memory, and many elderly people are experiencing the benefits of plasmalogens.

  • The product contents are the same as the current version.

  • REMORY® is a registered trademark in the United States.

  • The sea squirt-derived plasmalogens in REMORY® have obtained a New Dietary Ingredient Notification (NDIN) in the U.S. The NDIN is a registration requirement by the FDA for nutritional components not previously sold as dietary supplements in the U.S.

  • "Food with Functional Claims" refers to a Japanese regulatory system where foods are registered with the Consumer Affairs Agency of Japan, based on scientific evidence for safety and functionality in accordance with Japanese regulations.

Contact Information

Takahito Tsuchiya
Director
info@hokkori-usa.com
310-347-8750

SOURCE: Hokkori USA, Inc.

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.